SG3185G - Compositions containing 1,3-dimethyl-5-aminoadamantane - Google Patents

Compositions containing 1,3-dimethyl-5-aminoadamantane

Info

Publication number
SG3185G
SG3185G SG31/85A SG3185A SG3185G SG 3185 G SG3185 G SG 3185G SG 31/85 A SG31/85 A SG 31/85A SG 3185 A SG3185 A SG 3185A SG 3185 G SG3185 G SG 3185G
Authority
SG
Singapore
Prior art keywords
aminoadamantane
dimethyl
compositions containing
compositions
Prior art date
Application number
SG31/85A
Other languages
English (en)
Original Assignee
Merz & Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz & Company filed Critical Merz & Company
Publication of SG3185G publication Critical patent/SG3185G/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG31/85A 1978-12-27 1985-01-11 Compositions containing 1,3-dimethyl-5-aminoadamantane SG3185G (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE2856393A DE2856393C2 (de) 1978-12-27 1978-12-27 Arzneimittel zur Behandlung von Morbus Parkinson

Publications (1)

Publication Number Publication Date
SG3185G true SG3185G (en) 1985-06-14

Family

ID=6058522

Family Applications (1)

Application Number Title Priority Date Filing Date
SG31/85A SG3185G (en) 1978-12-27 1985-01-11 Compositions containing 1,3-dimethyl-5-aminoadamantane

Country Status (10)

Country Link
US (1) US4273774A (fr)
JP (1) JPS5589219A (fr)
BE (1) BE880905A (fr)
CA (1) CA1121726A (fr)
DE (1) DE2856393C2 (fr)
FR (1) FR2445145A1 (fr)
GB (1) GB2044098B (fr)
NL (1) NL7909307A (fr)
SE (1) SE448517B (fr)
SG (1) SG3185G (fr)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE33080E (en) * 1981-08-31 1989-10-03 Exxon Research And Engineering Company Adamantane catalyzed paraffin isomerization
US5506231A (en) * 1989-03-31 1996-04-09 The Children's Medical Center Corporation Treatment of aids dementia, myelopathy and blindness
US5455279A (en) * 1991-04-19 1995-10-03 The Children's Medical Center Corporation Regimen method of mediating neuronal damage using nitroglycerine
US5614560A (en) * 1991-04-04 1997-03-25 Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
DE19707655A1 (de) * 1997-02-26 1998-08-27 Hoechst Ag Kombinationspräparat zur Anwendung bei Demenz
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
TW200418446A (en) 2002-10-24 2004-10-01 Merz Pharma Gmbh & Co Kgaa Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
EP2260844A1 (fr) * 2003-05-27 2010-12-15 Merz Pharma GmbH & Co. KGaA Combinaison d'un antagoniste de récepteur NMDA et d'un inhibiteur de la recapture sélective de la sérotonine pour le traitement de la dépression et d'autres troubles de l'humeur
MXPA05012810A (es) * 2003-06-16 2006-02-13 Allergan Inc Formas de dosis oral de memantina.
WO2005079779A1 (fr) * 2003-10-22 2005-09-01 Merz Pharma Gmbh & Co. Kgaa Utilisation de derives de 1-aminocyclohexane pour modifier le depot de peptides a$g(b) fibrillogenes dans des amyloidopathies
AR046314A1 (es) 2003-11-05 2005-11-30 Merz Pharma Gmbh & Co Kgaa Composiciones que comprenden ciclohexilaminas y aminoadamantanos
WO2005067908A2 (fr) * 2004-01-05 2005-07-28 Merz Pharma Gmbh & Co. Kgaa Memantine destinee au traitement de la maladie d'alzheimer legere et legere a moderee
US7456224B2 (en) * 2004-04-05 2008-11-25 Forest Laboratories Holdings, Ltd. Method for treating autism
US20060002999A1 (en) 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
JP5025468B2 (ja) 2004-06-17 2012-09-12 メルツ・ファルマ・ゲゼルシヤフト・ミト・ベシュレンクテル・ハフツング・ウント・コンパニー・コマンデイトゲゼルシヤフト・アウフ・アクティーン メマンチン又はネラメキサンの直接圧縮によって製造された、飲用に適した即効型錠剤
EA011446B1 (ru) * 2004-06-17 2009-02-27 Форест Лэборэтериз, Инк. Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением
TW200616608A (en) * 2004-07-09 2006-06-01 Forest Laboratories Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
WO2006034465A1 (fr) * 2004-09-23 2006-03-30 Merz Pharma Gmbh & Co. Kgaa Memantine pour le traitement des troubles du comportement de l'enfant
US7619007B2 (en) * 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
US20060205822A1 (en) * 2004-12-22 2006-09-14 Forest Laboratories, Inc. 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
ATE481096T1 (de) 2005-04-06 2010-10-15 Adamas Pharmaceuticals Inc Verfahren und zusammensetzungen zur behandlung von zns-erkrankungen
EP1898890A1 (fr) * 2005-06-16 2008-03-19 Forest Laboratories, Inc. Formulation de gouttes de memantine a liberation modifiee et immediate
US20070099947A1 (en) * 2005-11-03 2007-05-03 Alkermes, Inc. Methods and compositions for the treatment of brain reward system disorders by combination therapy
EP2040676A2 (fr) * 2006-07-06 2009-04-01 Forest Laboratories, Inc. Formulations à dissolution orale de mémantine
MX2009001036A (es) 2006-08-04 2009-04-23 Merz Pharma Gmbh & Co Kgaa Pirazolopirimidinas, proceso para su preparacion y su uso como medicina.
WO2008063847A2 (fr) * 2006-11-03 2008-05-29 Forest Laboratories Holdings Limited Méthode de traitement de l'autisme
EP2085398A1 (fr) 2008-02-01 2009-08-05 Merz Pharma GmbH & Co. KGaA Pyrazolopyrimidines, leur procédé de préparation et leur utilisation en tant que médicament
EP2090576A1 (fr) 2008-02-01 2009-08-19 Merz Pharma GmbH & Co.KGaA 6-halo-pyrazolo[1,5-a]pyridines, leur procédé de préparation et leur utilisation en tant que modulateurs des récepteurs metabotropiques du glutamate (mGluR)
WO2009151498A2 (fr) * 2008-03-28 2009-12-17 Forest Laboratories Holdings Limited Formulations de mémantine
EP2288345B1 (fr) 2008-04-18 2015-06-10 University College Dublin National University Of Ireland, Dublin Produits psycho-pharmaceutiques
EP2111858A1 (fr) 2008-04-25 2009-10-28 EPFL Ecole Polytechnique Fédérale de Lausanne Nouveau traitement pour la maladie d'Alzheimer
US20090275597A1 (en) * 2008-05-02 2009-11-05 Forest Laboratories Holdings Limited Methods of treating cns disorders
EP2138173A1 (fr) 2008-06-26 2009-12-30 Merz Pharma GmbH & Co.KGaA Compositions pharmaceutiques comportant des dérivés d'aminoadamantane
TW201116532A (en) 2009-08-05 2011-05-16 Merz Pharma Gmbh & Co Kgaa Metabotropic glutamate receptor modulators
CA2994873A1 (fr) 2009-12-02 2011-06-09 Adamas Pharma, Llc Compositions d'amantadine et procedes d'utilisation associes
US20110251239A1 (en) 2010-04-07 2011-10-13 Eisai Inc. Combination therapy for the treatment of dementia
AR083475A1 (es) 2010-10-18 2013-02-27 Merz Pharma Gmbh & Co Kgaa Moduladores de receptores de glutamato metabotropicos
MX2013004760A (es) 2010-10-29 2013-07-02 Merz Pharma Gmbh & Co Kgaa Derivados de indol y proceso para su preparacion.
EP3034079B1 (fr) 2010-11-15 2018-01-10 Agenebio, Inc. Dérivés de pyridazine, compositions et méthodes de traitement d'une déficience cognitive
AR084515A1 (es) 2010-12-22 2013-05-22 Merz Pharma Gmbh & Co Kgaa Derivados heterociclicos nitrogenados, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades asociadas al sistema nervioso central tales como parkinson y alzheimer, entre otras
AR084516A1 (es) 2010-12-22 2013-05-22 Merz Pharma Gmbh & Co Kgaa Moduladores de receptores de glutamato metabotropicos
WO2012152854A1 (fr) 2011-05-12 2012-11-15 Merz Pharma Gmbh & Co. Kgaa Modulateurs de récepteur de glutamate métabotropique
WO2012172093A1 (fr) 2011-06-17 2012-12-20 Merz Pharma Gmbh & Co. Kgaa Dérivé de dihydroindolizine à titre de modulateurs des récepteurs métabotropes de glutamate
EP2650284A1 (fr) 2012-04-10 2013-10-16 Merz Pharma GmbH & Co. KGaA Dérivés hétérocycliques comme modulateurs de récepteurs du glutamate métabotropique
RU2488388C1 (ru) 2012-05-24 2013-07-27 Ооо "Валента Интеллект" Фармацевтическая композиция для профилактики и лечения психических, поведенческих, когнитивных расстройств
DK2892540T3 (en) * 2012-09-06 2018-11-19 Mcpharma Biotech Inc TREATMENT OF DIARRES AND DRAWN DIARRES WITH RESISTANT POTATO STARCH
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
NZ760341A (en) 2013-12-20 2021-12-24 Agenebio Inc Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
EP3102186B1 (fr) 2014-02-04 2021-01-27 Forest Laboratories Holdings Limited Compositions de donépézil et procédé de traitement de la maladie d'alzheimer
MX392119B (es) 2015-06-19 2025-03-11 Agenebio Inc Derivados de benzodiazepina, composiciones y metodos para tratar deterioro cognitivo
US10966936B2 (en) 2015-12-30 2021-04-06 Corium, Inc. Systems comprising a composite backing and methods for long term transdermal administration
WO2017223402A1 (fr) 2016-06-23 2017-12-28 Corium International, Inc. Matrice adhésive à un domaine hydrophile, un domaine hydrophobes et un agent thérapeutique
CN116270551A (zh) 2016-07-27 2023-06-23 考里安有限责任公司 通过盐至中性药物原位转化的组合物、透皮贴剂及应用
EP3490544A1 (fr) 2016-07-27 2019-06-05 Corium International, Inc. Systèmes d'administration transdermique de mémantine
WO2018022814A1 (fr) 2016-07-27 2018-02-01 Corium International, Inc. Systèmes d'administration transdermique à pharmacocinétique bioéquivalent à l'administration orale
US11505555B2 (en) 2016-12-19 2022-11-22 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US10369187B2 (en) 2017-02-09 2019-08-06 Vanderbilt University Peptide regulators of JNK family kinases
US11173132B2 (en) 2017-12-20 2021-11-16 Corium, Inc. Transdermal adhesive composition comprising a volatile liquid therapeutic agent having low melting point
CN112601749B (zh) 2018-06-19 2024-03-26 艾吉因生物股份有限公司 用于治疗认知损害的苯并二氮杂环庚三烯衍生物,组合物和方法
CN119095622A (zh) 2022-02-08 2024-12-06 菲克雷特·萨欣 Nmdar拮抗剂通过提高20s蛋白酶体活性来预防老化和老化相关病况和疾病
CN120584115A (zh) 2022-08-19 2025-09-02 艾吉因生物股份有限公司 苯并氮杂䓬衍生物、组合物和用于治疗认知损害的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3864489A (en) * 1972-03-20 1975-02-04 Gen Foods Corp Treatment of hyperkinetic conditions with caffeine
ES413944A1 (es) * 1972-04-20 1976-06-01 Merz & Co Procedimiento para la preparacion de compuestos de adamen- tano trisustituidos en las posiciones 1,3,5.
AU6889274A (en) * 1973-05-17 1975-11-20 Astra Laekemedel Ab Treatment of neurological disorders
DE2518677A1 (de) * 1974-05-06 1975-11-20 Sandoz Ag Neue pharmazeutische zubereitungen

Also Published As

Publication number Publication date
US4273774A (en) 1981-06-16
DE2856393C2 (de) 1983-04-28
BE880905A (fr) 1980-06-27
FR2445145A1 (fr) 1980-07-25
SE448517B (sv) 1987-03-02
SE7910501L (sv) 1980-06-28
FR2445145B1 (fr) 1984-10-26
GB2044098A (en) 1980-10-15
DE2856393A1 (de) 1980-07-03
JPS5589219A (en) 1980-07-05
GB2044098B (en) 1983-01-26
NL7909307A (nl) 1980-07-01
CA1121726A (fr) 1982-04-13

Similar Documents

Publication Publication Date Title
SG3185G (en) Compositions containing 1,3-dimethyl-5-aminoadamantane
JPS54139654A (en) Composition
GB2011917B (en) Rubber compositions containing 1,2-polybutadience
IL60491A0 (en) 2,2-difluoro-6a-carba-pgi2 compounds
IL57923A (en) 1,2,3,5-tetrahydroimidazothienopyrimidin-2-ones
ZA796336B (en) 1,2,4,5-tetra-alkyl-4-arylpiperidines
IL58478A0 (en) Pharmaceutical composition containing 3,4-dihydro-3-oxo-2-quinoxalines
JPS54152038A (en) Flameeproof*lowwsmoke hottmelt composition
JPS54107993A (en) Alphaacyanoacrylate composition
GB2034704B (en) 2,6-daiminonebularines
JPS54147931A (en) Antiiulcer composition
GR64915B (en) Improved etomidate-containing compositions
PT69935A (en) Insecticidals compositions
IL56443A0 (en) 2,6-dinitrobenzeneamines
GB2087873B (en) 1,2-dioximes
GB2021108B (en) 6,7 - di - 4 - amino - 2 - quinazolines
ZA793302B (en) Fasciolicidal compositions
PT69225A (en) Compositions
PH17142A (en) 6,7-benzomorphans
JPS54147934A (en) Antiiangina composition
GB2018769B (en) 2,3-dihydro-4h-1-benzopyran-4-one o-carbamoyl-oximes
PT70100A (en) Farmaceutical compositions
GB2026861B (en) Pharmaceutical compositions containing 5-methyl-7-diethylamino-s-triazolo (1,5- )-pyrimidine
GB2032431B (en) 2,3 - dimethyl - pent - 4en - aldehyde
GB2026532B (en) Dtergent composition